The CRC Digest

Curated CRC research — accessible, accurate, actionable

Tuesday, April 21, 2026

1 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ◇ Pesticide exposure linked to early-onset colorectal cancer through epigenetic markers

  Analysis of 31 early-onset CRC patients (under 50) versus 100 late-onset patients (70+) identified the herbicide picloram as a new risk factor, with findings replicated across nine cohorts and validated in 94 US counties over 21 years. (Nature Medicine)

• ▪ Patient navigation identifies rural barriers to colonoscopy screening
• ◇ New ERK activation pathway discovered in colorectal cancer

  Researchers identified MTPN as a crucial regulator driving ERK hyperactivation through a noncanonical mechanism, offering a potential therapeutic target that blocks ERK signaling without inducing pathway reactivation. (Oncogene)

• ▸ Biomimetic nanoparticles enhance checkpoint blockade by remodeling tumor stiffness

  Platelet membrane-coated nanoparticles carrying Defactinib and PD-L1 antibodies reduced tumor matrix rigidity and improved immune cell infiltration in preclinical CRC models, suggesting a strategy to overcome checkpoint inhibitor resistance. (Journal of Nanobiotechnology)

Stay informed as research continues to advance our understanding of colorectal cancer prevention, detection, and treatment.